Granulocyte colony-stimulating factor (G-CSF) induces a transient mobilization of hematopoietic progenitor cells from bone marrow to peripheral blood. Our aim was to evaluate safety of repeated courses of G-CSF in patients with amyotrophic lateral sclerosis (ALS), assessing disease progression and changes in chemokine and cytokine levels in serum and cerebrospinal fluid (CSF). Twenty-four ALS patients entered an open-label, multicenter trial in which four courses of G-CSF and mannitol were administered at 3-month intervals. Levels of G-CSF were increased after treatment in the serum and CSF. Few and transitory adverse events were observed. No significant reduction of the mean monthly decrease in ALSFRS-R score and forced vital capacity was observed. A significant reduction in CSF levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-17 (IL-17) was observed. G-CSF treatment was safe and feasible in a multicenter series of ALS patients. A decrease in the CSF levels of proinflammatory cytokines MCP-1 and IL-17 was found, indicating a G-CSF-induced central anti-inflammatory response.

Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study / A. Chiò, G. Mora, V. La Bella, C. Caponnetto, G. Mancardi, M. Sabatelli, G. Siciliano, V. Silani, M. Corbo, C. Moglia, A. Calvo, R. Mutani, S. Rutella, F. Gualandi, M. Melazzini, R. Scimè, M. Petrini, P. Bondesan, S. Garbelli, S. Mantovani, C. Bendotti, C. Tarella, P. Ghiglione, P. Omedé, M. Ulla, M. Mascolo, C. Carlesi, P.A. Tonali, A. Conte, M. Luigetti, D. Alimonti, F. Onida, P. Bossolasco, G.L. Deliliers, F. Valentino. - In: MUSCLE & NERVE. - ISSN 0148-639X. - 43:2(2011), pp. 189-195. [10.1002/mus.21851]

Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study

V. Silani;C. Tarella;F. Onida;
2011

Abstract

Granulocyte colony-stimulating factor (G-CSF) induces a transient mobilization of hematopoietic progenitor cells from bone marrow to peripheral blood. Our aim was to evaluate safety of repeated courses of G-CSF in patients with amyotrophic lateral sclerosis (ALS), assessing disease progression and changes in chemokine and cytokine levels in serum and cerebrospinal fluid (CSF). Twenty-four ALS patients entered an open-label, multicenter trial in which four courses of G-CSF and mannitol were administered at 3-month intervals. Levels of G-CSF were increased after treatment in the serum and CSF. Few and transitory adverse events were observed. No significant reduction of the mean monthly decrease in ALSFRS-R score and forced vital capacity was observed. A significant reduction in CSF levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-17 (IL-17) was observed. G-CSF treatment was safe and feasible in a multicenter series of ALS patients. A decrease in the CSF levels of proinflammatory cytokines MCP-1 and IL-17 was found, indicating a G-CSF-induced central anti-inflammatory response.
amyotrophic lateral sclerosis; clinical trial; granulocyte colony-stimulating factor; hematopoietic stem cells; neuroinflammation
Settore MED/15 - Malattie del Sangue
2011
Article (author)
File in questo prodotto:
File Dimensione Formato  
Chi-_et_al-2011-Muscle_%26_Nerve.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 210.2 kB
Formato Adobe PDF
210.2 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/297856
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 61
  • ???jsp.display-item.citation.isi??? 54
social impact